Team

Management

Michael McFadden, BBA

Chief Executive Officer

Michael McFadden, BBA

Chief Executive Officer

Mr. McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology and urology. Mr. McFadden most recently served as chief commercial officer of MPower Health, an orthopedic healthcare services company focused on value-based care solutions and interoperative neuromonitoring clinical services. Previously, Mr. Mcfadden has served on executive teams with Urovant Sciences, a urology based public company, and Avanir Pharmaceuticals, a CNS focused company, which was purchased by Otsuka Pharmaceutical Co, Ltd. In 2015. Earlier in his career, Mr. Mcfadden served in leadership roles at Amylin Pharmaceuticals, Pharmacia, and Eli Lilly and Company. He serves on advisory boards for MPower Health, and also MindLab, LLC, a company focused on therapeutics for pain management. Mr. Mcfadden holds a Bachelors In Business Administration from Northeast Louisiana University.

Fred Sancilio, MS, PhD

President and Director

Fred Sancilio, MS, PhD

President and Director

Dr. Sancilio has over 35 years of experience in pharmaceutical development and research. He has founded several biopharmaceutical companies including aaiPharma (CDMO renamed Alcami), Endeavor Pharmaceuticals (acquired by Barr Laboratories now Teva) and Aesgen, Inc. (now owned by Pfizer). Dr. Sancilio has been a board member of both public and private pharmaceutical companies and served as an advisor to Comvest Partners and Noble Financial Corporation; investment banking and investment organizations. More recently, he served as Research Professor at Florida Atlantic University. He was elected as a member of Sigma Xi, the Scientific Research Society of North America and holds both a Masters and Doctorate from Rutgers the State University of New Jersey.

Lauren D’Angelo, MBA

Chief Commercial Officer

Lauren D’Angelo, MBA

Chief Commercial Officer

Ms. D’Angelo brings more than 20 years’ experience leading successful drug commercialization efforts across 10 therapeutic areas, including multiple CNS therapies. She most recently served as Vice President, Marketing and Commercial Strategy at Urovant Sciences, where she joined the company as employee #3, and led the commercial launch of GEMTESA®, the first new Overactive Bladder (OAB) drug treatment in more than 10 years. Prior to Urovant Sciences, Ms. D'Angelo held leadership roles in commercial development, marketing, operations and sales at Avanir Pharmaceuticals, Medivation, Genentech, and AstraZeneca. She has participated in more than 10 successful pharmaceutical drug launches, six of which have become blockbuster brands. Ms. D’Angelo was recognized as Medical Marketing & Media's 2017 Woman to Watch and was selected as one of Pharmaceutical Executive's Emerging Pharma Leaders for 2020. Ms. D'Angelo received her B.S. in Management Information Systems and Finance from Florida State University and her MBA from the University of Florida.

Denis Kay, MSc, PhD

Chief Scientific Officer

Denis Kay, MSc, PhD

Chief Scientific Officer

Dr. Kay founded NLS in August 2006 and has acted as NLS’s Chief Scientific Officer for the last 14 years and ACI’s Chief Scientific Officer since 2017. Dr. Kay has more than 25 years of experience in the development and characterization of neurological conditions. He is a grant recipient of the Michael J. Fox Foundation and has received funding from numerous agencies for research and product development programs. Dr. Kay is a graduate of Dalhousie (B.Sc. and M.Sc.) and McGill (Ph.D.) Universities and has contributed publications to over 40 scientific journals. Dr. Kay also held teaching assistantship positions at Dalhousie and McGill Universities, and was a lecturer at McGill University.

Jeremy Wright, BA

Chief Financial Officer

Jeremy Wright, BA

Chief Financial Officer

Mr. Wright has broad experience working with senior management developing strategies and solutions to business issues mainly related to corporate finance, cost and risk management, and governance. Mr. Wright is a Chartered Professional Accountant (Certified Management Accountant), currently serves as President and CEO of Seatrend Strategy Group and as a director for several public and private companies including: Pontus Protein Ltd., Centurion Minerals Ltd., and Demetra Minerals Inc. Mr. Wright previously served as a director of TGS Esports Inc., Freeform Capital Partners Inc., Pacific Community Resources Society and the Canadian Freestyle Ski Association. In addition, Mr. Wright also serves as the CFO for several public and private companies, including: the Target Company, Portofino Resources Inc., and Centurion Minerals Ltd. He was previously the CFO for GTEC Cannabis Co., an ultra-premium cannabis producer having three federally licensed production facilities across Canada. Mr. Wright also holds a Bachelor of Arts, with honours in Environmental Economics, from Brock University.

Joseph Kates

Vice President – Corporate Operations

Joseph Kates

Vice President – Corporate Operations

Mr. Kates brings more than 20 years of broad pharma and biotech experience to the Corporate Operations function at Alpha Cognition.  Prior to Joining Alpha Cognition, Mr. Kates was the Executive Director of Business Operations at Urovant Sciences where he built out the IT, Analytics, Facilities and Operations functions from the ground up, prior to their acquisition by Sumitomo Dainippon Pharma.  Mr. Kates previously held operations leadership positions at Avanir Pharmaceuticals (acquired by Otsuka Pharmaceutical Co, Ltd.), and Azur Pharmaceuticals (acquired by Jazz Pharmaceuticals).  Mr. Kates holds a Bachelor of Science in Operations and Information Systems Management from The Pennsylvania State University.

Colleen Johns

SVP, Product Development

Colleen Johns

SVP, Product Development

Ms. Johns has more than 30 years of experience in the pharmaceutical industry, playing a key role in product development and regulatory strategy in support of numerous marketing applications across a variety of therapeutic fields.  She has extensive experience interacting with the FDA including meetings, negotiations and authoring multi-national regulatory documents.  Prior to joining Alpha Cognition, she held senior level positions in Regulatory Affairs at Dova Pharmaceuticals, Sucampo Pharmaceuticals, and Sancilio & Company, Inc.  Colleen has a B.S. in Biology (magna cum laude with honors) from University of North Carolina Wilmington and is also RAC certified through the Regulatory Affairs Professional Society (RAPS).

Directors

Len Mertz, BBA, MPA

Chairman

Len Mertz, BBA, MPA

Chairman

Mr. Mertz has over 35 years of experience as a CEO, board member, and investor in various venture-backed companies including Triumvira Immunologics, Akido Labs, and PeraHealth, of which he is chairman. In addition, he is Chairman of Shannon West Texas Memorial Hospital, a CMS rated 5-star hospital, with currently budgeted gross revenues exceeding $1 billion and he serves on the board of the First National Bank of Mertzon . Mr. Mertz is a cofounder of Mayne & Mertz, Inc. an oil & gas exploration company. He began his career as a certified public accountant and obtained his BBA in Finance with Highest Honors and his Masters in Professional Accounting both from the University of Texas at Austin.

John Havens, BS

Director

John Havens, BS

Director

Mr. Havens received his geology degree from Louisiana State University and has been the President of Seismic Exchange Inc. for over 40 years. SEI is a source for premium 2D and 3D seismic data for the upstream oil and gas industry and is the largest 2D seismic data owner and one of the largest 3D seismic data owners in North America. Mr. Havens is also the owner of a health spa in California and the owner of the Vista Valley Country Club. Mr. Havens has also served on the board of directors of The Fay School, Houston Oaks Club, Cal-a-Vie Health Spa and as Chairman-Elect of the YPO Gold Houston Chapter.

Phillip Mertz, AB

Director

Phillip Mertz, AB

Director

Mr. Mertz is a co-founder and partner of Cenizas Capital, an investment firm focused on public and private equity. In addition to the Target Company, he is an initial investor and board member of Secure Open Solutions, a cybersecurity firm that provides compliance services to defense contractors. He also co-founded Py Square, a software development company that makes practical software solutions for the legal industry, and he is a partner in the investment group, Mertz Holdings. Previously he led business development for a natural gas fuel start-up, CNG Energy, and worked as a management consultant with Touchstone Consulting Group in Washington D.C. He graduated from Harvard University in 2006 with an A.B. in economics.

Rajeev ‘Rob’ Bakshi, BBA

Director

Rajeev ‘Rob’ Bakshi, BBA

Director

Mr. Bakshi was the co-founder of technology company, Silent Witness Enterprises Ltd., which was listed on the TSX and NASDAQ. He oversaw the company’s growth strategy before being sold to Honeywell for approximately $90 million in 2003. Since then, he has been involved with industrial land development, building a Convention Centre in Calgary and other strategic investments. In 2009, Mr. Bakshi began working with a South Korean company to establish Apivio Systems Inc. He led the strategy to turn the business into a Canadian company, putting together an independent board of directors, financing, and corporate governance in his capacity of Executive Chairman. In 2013, he was appointed CEO and was responsible for taking the company public. Apivio Systems Inc. was acquired by Nuri Telecom Company in an all-cash transaction in the spring of 2017.

Ken Cawkell, LLB

Director and Founder

Ken Cawkell, LLB

Director and Founder

Mr. Cawkell has been involved for over 25 years in the biotech industry as both a professional advisor, investor and as the founding principal of Alpha Cognition and its predecessor the Neurodyn Group. He is a member of the British Columbia Bar Association and in 1987, he co-founded the law firm Cawkell Brodie LLP. Mr. Cawkell has gained extensive strategic and development experience and has a history of value creation, as a result of his long-term association with numerous public and private companies. He has been involved in several successful exits and currently sits on the Board of TSE listed Well Health Technologies a leading integrated health care provider. He is a past member of the National Research Council of Canada IMB/INH Advisory Board and a number of biotech industry associations.

Dr. Frederick Sancilio, MS,PhD

President and Director

Dr. Frederick Sancilio, MS,PhD

President and Director

Dr. Sancilio has over 35 years of experience in pharmaceutical development and research. He has founded several biopharmaceutical companies including aaiPharma (CDMO renamed Alcami), Endeavor Pharmaceuticals (acquired by Barr Laboratories now Teva) and Aesgen, Inc. (now owned by Pfizer). Dr. Sancilio has been a board member of both public and private pharmaceutical companies and served as an advisor to Comvest Partners and Noble Financial Corporation; investment banking and investment organizations. More recently, he served as Research Professor at Florida Atlantic University. He was elected as a member of Sigma Xi, the Scientific Research Society of North America and holds both a Masters and Doctorate from Rutgers the State University of New Jersey.

Michael McFadden, BBA

CEO and Director

Michael McFadden, BBA

CEO and Director

Mr. McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology and urology. Mr. McFadden most recently served as chief commercial officer of MPower Health, an orthopedic healthcare services company focused on value-based care solutions and interoperative neuromonitoring clinical services. Previously, Mr. Mcfadden has served on executive teams with Urovant Sciences, a urology based public company, and Avanir Pharmaceuticals, a CNS focused company, which was purchased by Otsuka Pharmaceutical Co, Ltd. In 2015. Earlier in his career, Mr. Mcfadden served in leadership roles at Amylin Pharmaceuticals, Pharmacia, and Eli Lilly and Company. He serves on advisory boards for MPower Health, and also MindLab, LLC, a company focused on therapeutics for pain management. Mr. Mcfadden holds a Bachelors In Business Administration from Northeast Louisiana University.

Corporate

Read More

Latest News

View All

TSX-V: ACI

15 min delay
Last$20.05
Change$-0.21
Open20.41
Vol1685357
High20.78
Low20.05
Stock Information